share_log

EF Hutton Maintains Buy on CARISMA Therapeutics, Maintains $24 Price Target

Benzinga ·  Nov 7 21:32

EF Hutton analyst Jason Kolbert maintains CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $24 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment